Albany Molecular Research Inc. (AMRI) Posts 15% Increase in Q1 Earnings
Albany Molecular Research Inc., a scientific services provider, yesterday reported financial and operating results for the first quarter ended March 31, 2011. Total revenue for the first quarter of 2011 was $56.9 million, an increase of 15 percent compared to total revenue of $49.3 million reported in the first quarter of 2010. The company recognized recurring royalties of $14 million in the first quarter of 2011, a 34 percent increase from royalties of $10.4 million in the first quarter of 2010. The company earns royalties from worldwide sales of the non-sedating antihistamine Allegra® (Telfast® outside the United States), as well…